Daphne Karydas Sells 3,000 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Director Daphne Karydas sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $28.58, for a total value of $85,740.00. Following the completion of the sale, the director owned 6,200 shares of the company’s stock, valued at $177,196. The trade was a 32.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mineralys Therapeutics Stock Up 1.6%

NASDAQ MLYS traded up $0.44 on Thursday, reaching $27.98. 1,141,567 shares of the stock traded hands, compared to its average volume of 1,267,498. The company has a debt-to-equity ratio of 0.18, a quick ratio of 34.46 and a current ratio of 34.46. The company has a fifty day moving average price of $27.15 and a 200-day moving average price of $27.12. The company has a market cap of $2.47 billion, a price-to-earnings ratio of -6.60 and a beta of 0.68. Mineralys Therapeutics, Inc. has a 12 month low of $22.30 and a 12 month high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($2.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($2.30). As a group, research analysts forecast that Mineralys Therapeutics, Inc. will post -4.45 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently commented on MLYS shares. Jefferies Financial Group restated a “hold” rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. HC Wainwright reaffirmed a “buy” rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. Wall Street Zen lowered Mineralys Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Friday, July 17th. Finally, Zacks Research upgraded Mineralys Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, September 11th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Mineralys Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.80.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. BlueCrest Capital Management Ltd purchased a new stake in Mineralys Therapeutics in the second quarter valued at approximately $2,298,000. WINTON GROUP Ltd acquired a new stake in Mineralys Therapeutics during the 2nd quarter valued at approximately $912,000. Arizona State Retirement System lifted its stake in Mineralys Therapeutics by 22.4% during the 2nd quarter. Arizona State Retirement System now owns 15,357 shares of the company’s stock valued at $414,000 after acquiring an additional 2,815 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Mineralys Therapeutics in the 2nd quarter valued at $333,000. Finally, Pale Fire Capital SE boosted its holdings in shares of Mineralys Therapeutics by 68.0% in the 2nd quarter. Pale Fire Capital SE now owns 614,284 shares of the company’s stock valued at $16,573,000 after acquiring an additional 248,658 shares during the last quarter. 84.46% of the stock is currently owned by hedge funds and other institutional investors.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and kidney-related diseases. The company’s research is centered on conditions associated with excess aldosterone activity, including uncontrolled and resistant hypertension.

Mineralys’ lead investigational product is lorundrostat, also known as MLS-101, an oral, highly selective aldosterone synthase inhibitor. The company is evaluating lorundrostat in clinical studies as a potential treatment for patients whose blood pressure remains inadequately controlled despite existing therapy.